The Aptuit Center for Drug Discovery & Development Verona, Italy

Similar documents
EARLY PHASE DEVELOPMENT SOLUTIONS

UNLEASH THE POWER OF PRECISION MEDICINE

SPEED UP YOUR TIME TO MARKET

OUR MISSION OUR EXPERTISE OUR SERVICES

From Discovery to Development of new Drugs. and pitfalls along the way. by Kim Dekermendjian, PhD in Medicine BD & Key Account manager

Finding the right partner for preclinical into phase I. Facts, Threats & Opportunities

Optimisation de votre programme de développement

Antibody Discovery at Evotec

EARLY DRUG DEVELOPMENT CONSULTANCY & SERVICES CLINICAL RESEARCH SOLUTIONS

NIH-RAID: A ROADMAP Program

PPD LABORATORIES COMPREHENSIVE SERVICES

Explore the World of End-to-End. Integrated Lab Performance

CYP INDUCTION QWBA PROTEIN BINDING CYP INHIBITION RADIOLABEL MASS BALANCE DMPK OVERVIEW XENOGRAFT MODELS ADME SUMMARY REPORT.

Introduction to Drug Design and Discovery

From Bench to Bedside. Russ H. Read June 23, 2014

Your bridge to. better medicines

to acquire Investor And Analyst Call Presentation January 4, 2008

AT A GLANCE. inventivhealthclinical.com

The Right Molecules. Designed. Delivered.

Integration of FDSS7000 into a modular robotic system for Open Innovation drug discovery

GxP Auditing, Remediation, and Quality System Resourcing

Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date

DMPK Overview. QPS is your Global Link to all your DMPK Sourcing Needs DMPK OVERVIEW CYP INDUCTION QWBA PROTEIN BINDING CYP INHIBITION

A drug development crossroad lies ahead

BIOPHARMA SOLUTIONS TM Expedite Your Drug Development Program

Introduction of Development Center for Biotechnology TAIWAN

Services for Medical Devices. Expert solutions for product development from concept to commercialization

Investor Presentation. September 2018

Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing

Institute of Pharmaceutical Technology and Biopharmacy University of Pécs szeptember 22. 1

A full-service CRO with integrated early-stage capabilities

The Power to Cure: Therapeutic Innovation in Academia

"From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia

Science. People. Affordable and innovative medicines.

TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT

Jefferies Global Health Care Conference. June 1, 2015

Investor presentation. December 2018

Parioforma. Pharmaceutics Landscape - summary. (formerly RM Consulting) April 2005

We offer integral tailor-made solutions, providing our expertise, flexibility and capability from early stages to launch.

PRAXIS. A publication by Bioengineering AG

! Background. ! What is really new?! The new Section 7: Explorative Clinical Trials (ECTs) ! Consequences in General

AAV vectors for gene therapy. Any Gene to Any Cell

How Targets Are Chosen. Chris Wayman 12 th April 2012

Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms

Envigo Corporate & Industry Overview. Rutgers University

FDA Perspective on the Preclinical Evaluation of Biological Therapies for Cancer

Anti-cancer drug discovery: from bench to bedside

Dermal Studies at CBI

GxP Auditing, Remediation, and Staff Augmentation

博奥信生物技术 ( 南京 ) 有限公司. Biosion (China) Recruiting

Eurofins ADME BIOANALYSES Your partner in drug development

Cardinal Health Specialty Solutions. Bringing a new drug to life. Regulatory Sciences

the PLATFORM Pipeline in Lyon AREA

SHANGHAI MEDICILON INC.

Exploratory IND: a study proposal from Novartis

395 South Youngs Road Buffalo, New York cognigencorp.com An On-Site 2-Day Workshop in Engineering The Pharmacometric Enterprise

MDI Manufacturing Services

Applying Affimers. Dr Amanda Nicholl at Avacta Life Sciences. Improving Antibody PK Assay Development

The largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to

Agreed with W. Cornell Graduate Program and Tri-I

Competing & Collaborating to Achieve Successful Drug Repositioning

The Swedish Foundation for Strategic Research (SSF) announces a. call for proposals in the areas of

BioXplain The Alliance for Integrative Biology

ICH 교육가이드라인 [ 안전성 & 품질 ]

In Vitro Pharmacology Services

DRUG DISCOVERY AND DEVELOPMENT-PRECLINICAL ASPECTS

THE ANSWERS YOU NEED ARE ALL RIGHT HERE

A Global CRO STRONGER TOGETHER

Pharmaceutical Sciences

Position1: Senior Scientist/Principal Scientist

ND4BB Topic 3: Discovery and development of new drugs combatting Gram-negative infections

Non-Dilutive Funding for Opportunities for CNS/PNS Related R&D

R&D of Biological Products. Rochapon Wacharotayankun, Ph.D., R.Ph.

GxP Auditing, Remediation, and Staff Augmentation

NUVISAN GROUP. Our Philosophy

Accelerating development of enabled formulations for poorly soluble drugs

The Exploratory IND (Phase 0) Concept

Successful Academia-Pharma Collaboration Drug Discovery and Clinical Development

INSIGHT-DRIVEN FORMULATIONS DEVELOPMENT

3M Drug Delivery Systems. April 26, 2011

Key Resources in Biomedical Product Development

in full-service contract pharmaceutical development and manufacturing

National Academic Reference Standards (NARS) Pharmacy. January st Edition

MASTER IN PHARMACEUTICAL SCIENCES (Thesis Track)

ADB Consulting & CRO Inc.

Duncan Holmes European Head Discovery Partnerships with Academia GlaxoSmithKline

Oral Dosage Formulation Development

Impurities in Drugs: Monitoring, Safety and Regulation The Israel Chapter of PDA

Translational Pharmaceutics : a unique platform to accelerate early oncology development

Get to market. You want to develop medical devices that are safe, effective, and compliant. We ll show you the most efficient path.

BioXplain The Alliance for Integrative Biology The First Open Platform for Iterative, Predictive and Integrative Biology

Table of Contents. Welcome to Dishman. Our Mission. Our Focus: Client Satisfaction

Comments and suggestions from reviewer

Toxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development

BioProcess Technology Group. Helping Clients De-Risk Biopharmaceutical Development Since 1994

KRISANI BIO SCIENCES PVT. LTD.

NIAID Resources to Facilitate Medical Countermeasure Development

Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development

CONTRACT RESEARCH SERVICES

Transcription:

The Aptuit Center for Drug Discovery & Development Verona, Italy

2 The Aptuit Center for Drug Discovery & Development Verona, Italy Aptuit in Verona: uncommon expertise, exceptional results A knowledgeable scientific group, comprised of some of the industry s foremost drug discovery and development experts, forms a collaborative team at The Aptuit Center for Drug Discovery & Development in Verona, Italy. They are specialists with uncommon expertise in neuroscience, antibacterial, oncology, cardiovascular, respiratory and other key therapeutic areas. Together, with our other development sites in the US and the UK, these experts stand among Aptuit s vast, global assembly of talented people. Essential throughout the development process is the Project Manager who serves as the client s advocate and ensures exceptional results. Focused on the fastest, most efficient and lowest risk option, Aptuit s Project Managers are highly experienced professionals who fully understand that the client and Aptuit are most effective when working together in a partnership that is flexible, trustworthy and transparent.

The Best of Both Worlds: a CDDO and an R&D Engine The Aptuit facilities in Verona, Italy, combine the proven efficiency of a Contract Drug Development Organization (CDDO) with the established scientific expertise of an accomplished and successful Research and Development engine. When compared to typical contract providers, it is significant that the experience of much of the scientific staff has been attained within the pharmaceutical industry, rather than simply for the pharmaceutical industry. Scientists at the facilities have advanced a large number of molecules from early discovery through clinical development with low attrition rates on many target classes. Their expertise in multiple therapeutic areas imparts a strong measure of confidence and credibility for pharmaceutical clients. Working as a highly integrated team, Aptuit scientists take a solution-driven approach, progressing compounds efficiently, expeditiously and economically. GMP authorization for both API and drug manufacturing and testing facilities are in place with regulatory inspections performed by AIFA, the Italian Drug Agency, and the FDA. Preclinical facilities for biological studies are fully GLP certified by the Italian Ministry of Health according to OECD principles. GCP compliance has also been determined for testing of human samples and management of clinical studies. 3

4 The Aptuit Center for Drug Discovery & Development Verona, Italy Integrated Knowledge: a unique, dynamic differentiator Integrated Knowledge captures all that is exceptional about The Aptuit Center for Drug Discovery & Development. The term stands for the essence of what clients whether they represent large, multinational companies or emerging biotechs can anticipate as a unique, reliable and consistent advantage when they select Aptuit as their partner. Specifically, Integrated Knowledge represents layer upon layer of the insights and understanding of a collaborative group of multidisciplinary scientific experts and their support teams who routinely have access to the most advanced technologies. The Integrated Knowledge of scientific professionals in Drug Design & Discovery, Preclinical Biosciences, Pharmaceutical Sciences and Clinical Strategy is a significant and dynamic Aptuit differentiator. Integrated Knowledge is the driving force in taking the client s molecule through to finished drug product with maximum efficiency.

Benefits for both integrated and stand alone services Whether clients choose an Integrated Service Offering or select stand alone services, they experience the Integrated Knowledge of scientists at The Aptuit Center for Drug Discovery & Development, who share an insatiable quest for learning and are able to grasp all the subtleties and implications of the entire picture. Their all-encompassing vision of the process, always in the spirit of sharing their individual knowledge with each other, allows for a deeper, greater understanding of the parameters set forth by the client. Significantly, the broadened perspective of Integrated Knowledge allows for the identification of challenges that may surface later on in the process. Therefore, as the process unfolds, Integrated Knowledge mitigates risks by anticipating potential problems and suggesting preemptive solutions. The Aptuit Integrated Service Offering Target Validation DISCOVERY SERVICES Target To Lead Lead To Candidate DEVELOPMENT SERVICES Preclinical Development Clinical Development COMPUTATIONAL CHEMISTRY MEDICINAL CHEMISTRY DMPK & BIOANALYSIS STRUCTURAL AND ANALYTICAL SCIENCES PHARMACOLOGY & SAFETY PHARMACOLOGY API DEVELOPMENT & MANUFACTURING PHARMACEUTICAL DEVELOPMENT & MANUFACTURING TOXICOLOGY & PATHOLOGY CLINICAL STRATEGY 5

6 The Aptuit Center for Drug Discovery & Development Verona, Italy Fully integrated services from a single site The facility s broad range of integrated capabilities includes Drug Design and Discovery, Preclinical Biosciences, Pharmaceutical Sciences, Clinical Strategy and Integrated Drug Discovery and Development programs. For clients, fully integrated drug discovery and development services from a single site deliver a number of tangible benefits such as reduced timelines, cost effectiveness, elimination of technical or informational transfers and efficiency to provide rapid solutions. Successful processes are in place to advance the client s molecule from discovery to finished product. Drug Design and Discovery Rapid Solutions Reduced Timelines Preclinical Biosciences Integrated Drug Discovery and Development Improved Efficiency Pharmaceutical Sciences Cost Effectiveness Clinical Strategy

Experts in overcoming early development challenges The breadth of Aptuit s capabilities in Verona bring added value to clients who are accustomed to dealing with several suppliers. Clients experience convenience, time and cost savings, and an exceptional level of quality performance that is the result of well established collaborative expertise. Among the other notable capabilities available from The Aptuit Center for Drug Discovery & Development are Integrated Non-Human Primate Facilities and Applied Immunology services. A full range of exploratory/ preliminary, regulatory, investigative, customized and fit for purpose studies can be conducted. AAALAC accredited animal facilities and procedures are used. In addition, preclinical development studies of vaccine/viral vector/gene therapy, such as GLP biodistribution and virus shedding, are available. 7

8 The Aptuit Center for Drug Discovery & Development Verona, Italy Drug Design & Discovery from Target to Lead to Candidate Aptuit s comprehensive Drug Design & Discovery processes are led by scientists with experience in target identification and validation of preclinical candidate molecules. Core discovery services, available as a fully integrated offering or as stand alone services, include: Computational Chemistry, Medicinal Chemistry, Discovery Biology, Pharmacology, Drug Metabolism and Pharmacokinetics (DMPK), Safety Assessment, and Analytical Discovery Support. In addition, expertise in Toxicology, Pharmaceutical Sciences and Clinical Strategy capabilities are brought into the process for a truly translational approach. Aptuit can provide Drug Design & Discovery solutions exceeding those normally associated with CDDO offerings, providing a versatile range of value-added business options best suited to individual client needs. Among these unique options are bundled Drug Design & Discovery and Preclinical Biosciences services. The bundled Aptuit offering of these services from a single site delivers integrated capabilities of the highest quality at substantial cost savings.

A comprehensive range of Drug Discovery capabilities n Hit Identification: featuring UHit, Aptuit s comprehensive, alternative approach that employs Virtual HTS computational screening through 2D/3D descriptors and structure-based ligandbased de novo design, and Discovery Biology, targeting activity and selectivity screens (affinity and/or functional in recombinant cell lines or native tissue) n Integrated Lead Optimization: an advanced approach that relies on fully integrated research units, multi-factorial optimization and a Fit-for-Purpose strategy n Fast-Follower, Knowledge-Based & Back-up Strategies: innovating new chemistry for existing drugs/scaffolds to improve safety and efficacy profiles n Exploratory Development Assessment: including preliminary Safety and DMPK when there is a low quantity or poor quality of available API n Translational Biology and Safety Strategy: Bench to Bedside research that expedites the translation of scientific discoveries into clinical practice n IP Boost and Generation Engine n Due Diligence and Consulting Hit Identification Integrated Lead Optimization Due Diligence and Consulting DISCOVERY SERVICES Fast-Follower, Knowledge- Based & Back-up Strategies IP Boost and Generation Engine Translational Biology and Safety Strategy Exploratory Development Assessment 9

10 The Aptuit Center for Drug Discovery & Development Verona, Italy Preclinical Biosciences, taking a customized approach The Preclinical Biosciences team at The Aptuit Center for Drug Discovery & Development can perform the full spectrum of preclinical studies, with the assurance of accurate and balanced assessments even when meeting the tightest deadlines. Scientists employ best-in-class technologies to find the solutions that suit client s requirements. From laboratories within the Verona site, they share their expertise in Microbiology, Pharmacology and Safety Pharmacology, Toxicology & Pathology, Drug Metabolism & Pharmacokinetics and Preclinical and Clinical Bioanalysis. The integrated Aptuit team is distinguished by specialized preclinical capabilities. A legacy of success in applied immunology services and in conducting studies for biotherapeutics are notable. Preclinical Biosciences offers expertise in CNS disease, antibacterials, substance abuse, oncology, cardiovascular and other key therapeutic areas.

Experienced in the preclinical development of GTMPs The Preclinical Biosciences group is comprised of molecular and cellular biologists, immunologists and toxicology/pathology experts who are dedicated to projects related to the development of Gene Therapy Medicinal Products (GTMPs). The team can perform GLP studies for GTMPs that include integrated parallel toxicology/ pathology, efficacy and biodistribution studies, with flexible study plans to accelerate preclinical development. Before the release of the GTMP, quality tests on produced batches are performed, including: titer determination, pseudotyping identity (for viral vectors), residual DNA contamination, stability studies and transgene identity. A key component of GTMP development is quality control testing, including: Titer determination Pseudotyping identity (for viral vectors) Residual DNA contamination Stability studies Transgene identity 11

12 The Aptuit Center for Drug Discovery & Development Verona, Italy Pharmaceutical Sciences, all under one roof in Verona Aptuit clients can rely on fully integrated Pharmaceutical Sciences services from the Verona site. Well established capabilities in Chemical Development and Manufacturing, Pharmaceutical Development, Analytical and Physical Science and Clinical Supply conjoin to make Aptuit the ideal Pharmaceutical Sciences partner. The seamless integration of drug substance and drug product services, all performed under one roof in Verona, provides clients with a distinctive advantage: every aspect of their project is accomplished by a single, unified, collaborative team. Aptuit s Pharmaceutical Sciences team takes the big picture approach in the development of both drug substance (API) and drug product. The broadened perspective of Integrated Knowledge enables scientists to address early findings that foresee potential issues that might surface later on in the process, avoiding or mitigating the risks of unexpected delays and costs.

Complementary Vision, a novel way to deliver services Aptuit has initiated a new way of delivering Pharmaceutical Sciences, known as Complementary Vision. This harmonized approach encompasses all of the services that precede and follow the Pharmaceutical Sciences profile. Cost efficiency and time saving benefits through the design of the dosage form that best fits the preclinical/clinical needs are the result of this novel approach. Pharmaceutical Sciences clients can rely on a combination of in silico, in vitro and in vivo services. The results substantiate the design, development and selection of the most effective dosage form for the intended clinical use, throughout the application of biopharmaceutics from early to late development stages. A comprehensive review process is undertaken for generic drugs to meet up-to-date regulatory requirements. Expertise in API development and manufacturing ensures the timely delivery of the required quality of API to support both toxicological and clinical studies. Aptuit also provides the required analytical support, including method development and validation and batch release. Lean Six Sigma business processes are in place, helping to ensure total quality management. 13

14 The Aptuit Center for Drug Discovery & Development Verona, Italy Aptuit INDiGO, addressing today s challenges A significant solution to overcoming the time and cost challenges of drug development is Aptuit INDiGO. This accelerated development process uses integrated, parallel development tracks to advance API to regulatory submission in as few as 26 weeks. In just 52 weeks, compounds can progress from candidate selection to regulatory submission, a highly desirable alternative to the industry average of 122 weeks. By adding 30 additional weeks, Aptuit INDiGO takes the compound into the clinical phase and provides human safety, tolerability and pharmacokinetics results from First In Man studies. To date, Aptuit s multidisciplinary teams of experts have successfully implemented more than 60 Aptuit INDiGO packages across a wide range of therapeutic areas for small and large molecules, drug product changes, and post FIM and IP extension opportunities. Aptuit INDiGO can be customized to advance your molecule from candidate selection to FIM/POC studies World class preclinical safety/dmpk & solid state chemistry Quality-by-design principles applied in earliest stages Seamless data and knowledge integration throughout project Regulatory documentation preparation & Clinical Sciences Reduced service provider monitoring

Accelerated development, real time data When performed at The Aptuit Center for Drug Discovery & Development and other global sites, Aptuit INDiGO addresses other industry challenges by providing an integrated approach. The accelerated process overcomes the negative effects of dealing with multiple outsourcing companies or incurring difficulties created by inefficient handoff between multidisciplinary groups. Aptuit INDiGO also delivers a real time, high quality data package with interpretation in key development areas, not something that is commonly found when clients are working with other contract providers. Optimized timelines are achieved by using integrated, parallel development tracks Industry average based on Tufts CSDD analysis: 122 weeks (Compared with Aptuit INDiGO 52 week package) As few as 26 weeks from API availability to Regulatory Submission As few as 52 weeks from Candidate Selection to Regulatory Submission Only 30 additional weeks from Regulatory Submission to FIM study report 15

The Aptuit Center for Drug Discovery & Development Verona, Italy Via Alessandro Fleming 4 37135 Verona (VR) Italy +39 045 8218111 For information about Aptuit s services, please contact us: in Europe: +39 045 821 9333 in the US: 855-506-6360 email us at: expertise@aptuit.com www.aptuit.com Aptuit s Global Family of World Class Facilities Aptuit Corporate Headquarters, Greenwich, Connecticut West Lafayette, Indiana Glasgow, Scotland Oxford, England Aptuit SSCI is recognized around the world for its solid state chemistry leadership. Aptuit s Glasgow, Scotland site is known for its sterile fill finish and formulation development. Aptuit s API facilities in Oxford, England, feature strong competencies in API development and manufacture. APT/BRO/VERONASITE/5/14/V002